ராயல்டி கொள்முதல் ப்ரைஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Jaguar Health Signs Definitive Agreement for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
Jaguar Health Enters Binding Term Sheet for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
The Board of SolGold (LSE and TSX code: SOLG) is pleased to advise all shareholders and interested investors of the release of the Company s interim financial results for the half year ended 31 December 2020. The interim financial report is included as part of this announcement. Further, the Board advises shareholders and interested investors that the Company s website also contains access to additional information required to be filed on SEDAR in Canada in connection with the Company s quarterly financial period ended 31 December 2020. This additional information is available in the Financial Reports section of the Investor Centre on the Company s website: www.solgold.com.au
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
(2)
No royalty payments due for 18-24 months
Proceeds will be allocated to support regulatory activities associated with the Company s development pipeline, including funding the recently initiated pivotal clinical trial for crofelemer (Mytesi
®) for cancer therapy-related diarrhea (CTD), for which patient enrollment is progressing
SAN FRANCISCO, CA / ACCESSWIRE / December 23, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ( Jaguar or the Company ) today announced that the Company has signed an agreement (the Agreement ) with a secured lender (the Lender ) for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $6 million (the Royalty Purchase Price ) a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties of Mytesi